Autolus Therapeutics Plc (AUTL) has released an update to notify the public and investors about a regulation fd disclosure.
Autolus Therapeutics plc announced the FDA’s acceptance of their Biologics License Application for obecabtagene autoleucel, aimed at treating relapsed/refractory Adult B-Cell Acute Lymphoblastic Leukemia. The FDA has designated November 16, 2024, as the target decision date under the standard review process for CAR T therapies. The related details are provided as Exhibit 99.1 but are not considered legally “filed” for regulatory purposes.
For further insights into AUTL stock, check out TipRanks’ Stock Analysis page.